Finchley HealthCare Ventures Inc. Participates in Reverb Therapeutics 12 Million Financing
Reverb Therapeutics, a biotechnology company harnessing the natural immune system and cytokine signaling to treat life-threatening diseases, announced on February 19th, 2025, the closing of a USD $12 million financing led by founding investor Amplitude Ventures. Other participants in the round include the Multiple Myeloma Research Foundation’s venture philanthropy arm, the Myeloma Investment Fund, KdT Ventures, Finchley Healthcare Ventures, InBC, and Seido Capital.
Reverb’s novel Amplify•R™ platform combines bispecific antibody engineering with data-driven modelling of antibody interactions to modulate the actions of endogenous cytokines and redirect them to tissues of interest. Reverb’s lead AMP01 program blocks PD-1 while delivering endogenous IL-15, a key protein that expands and activates cytotoxic T cells.
“We are thrilled to support Reverb’s mission. The novelty of their bispecific antibody approach, the compelling preclinical data for their lead program, and the team’s top-tier expertise and commitment to excellence give us confidence that they can deliver on their promise to offer superior alternatives for patients with cancer and autoimmune disorders,” said Pierre Beauparlant, Ph.D., Executive Managing Director of Finchley HealthCare Ventures.
To read Reverb Therapeutics Financing Press Release: Reverb Therapeutics Raises USD $12 Million Seed Round Financing to Harness Cytokine Signaling With its Amplify•R™ Platform | Business Wire